Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
about
Genetic, immunological, and pharmacological strategies to generate improved oncolytic virusesSafety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters.Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.Release the hounds: virotherapy with immunotherapy.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myelomaInduction of antiviral genes by the tumor microenvironment confers resistance to virotherapyHSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapyOncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in vitro but have additive anti-myeloma activity in vivo.Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagySpatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.Oncolytic vaccines.Cancer and comparative imaging.Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.Oncolytic Immunotherapy for Treatment of Cancer.Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.Vesiculovirus neutralization by natural IgM and complement.Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitorsAmalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spreadMyxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma CellsPEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.Systemic virotherapy for multiple myeloma.The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activityComparative oncology evaluation of intravenous recombinant oncolytic Vesicular Stomatitis Virus therapy in spontaneous canine cancer.Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.Model-based rational design of an oncolytic virus with improved therapeutic potential.Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.Potential of oncolytic viruses in the treatment of multiple myeloma.Oncolytic Viruses for Multiple Myeloma Therapy.Estimation of Oncolytic Virus Populations within Tumors
P2860
Q26859879-72B386BE-8D2C-47B4-A40A-2773CDAFAD12Q33434692-7DFF7BCD-7753-45D5-B5A6-4892C4E08F4AQ34013572-327C3D8A-359D-46C9-86F1-B745EB7A680DQ34989252-039707D4-A3D1-4E11-8843-185DF0648ACAQ35861186-53F7415F-0D91-4AAD-BDEC-F84B29E27593Q36700466-24397B63-994A-4C27-B385-E58FB0CB315EQ36700481-00A4586A-08BA-454F-ABD2-E747BE3B2DC4Q36751597-F3CF6038-07EB-4151-86EF-0C861BA1AC45Q37031914-264883BE-8545-4872-A7D8-742FE0A45834Q37076976-F76234BA-B3F2-4152-8C7D-4502E80D827FQ37104963-A0F5424D-F543-430C-803A-611445B5380FQ37123143-26C2C965-EE2D-4DA2-BF76-E7C4F3EFE8F3Q37373616-8BEE36DA-3931-4CAB-BA0B-343BC79EE6C7Q37381298-D8EC56E7-6E9F-40CB-AD40-A26D1FA0F7B0Q37644099-D4B6C07A-1E39-4D74-B438-C841A57B50B9Q37681801-07097145-E697-4104-9CDC-E4C6B77BE24FQ38152474-8E124E30-85C4-472C-98CD-F7B1CA62F23BQ38220808-3D9DD1C3-BA92-4C50-B4C6-9CD3F184E7B4Q38261256-28F0D788-4F3E-4832-B273-2E6E0F8F53B5Q38734741-3F58AC13-E2F6-435C-A684-E8D6DFE1CB07Q38780400-81698A61-AE67-46E5-B94E-C56001D35279Q38848223-F4CB1924-B6C8-4C6C-A268-25F29FA1D42AQ38860227-B46FBBF9-C7DF-49B3-AE43-B75E454A7C8EQ39013686-A508608B-C7AF-4569-8E80-6C5C5405AB0EQ39096636-60DA3BE1-F4F6-494C-A5B5-0FBBF922A71BQ39127778-D2A1CD03-F328-45AA-AC50-C5747DBC8CE9Q39633869-AB97F253-CFF3-43EB-BB3E-4CE2718CC336Q39788723-44A4D934-4BC5-4E87-8A8B-BEC4019F42A3Q40087770-74446C88-F547-45D1-96EB-D137D59EFE40Q40182196-52B3B90D-A9E4-4601-B4F4-09A2777E9608Q41770092-44D0CB53-D9FA-4A8E-B1CC-26962472CA04Q45324545-4AB7352A-8411-49E2-90C9-747E01ED0FC9Q45324769-FFEDEBF5-A51B-4291-A5EC-B3F21D39FAEFQ45350759-162D498F-DA3B-4005-9318-F354B32A450BQ47326177-056E1274-A852-4D3C-8776-46396173F165Q52674773-2B1563B9-984F-4A93-A025-C915EAA002B2Q55515625-D5B127F2-7398-427F-962B-38147F8BC104Q57462027-B8D49C89-224A-40FF-838A-8041973CBB4D
P2860
Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Potent systemic therapy of mul ...... virus coding for interferon-β.
@ast
Potent systemic therapy of mul ...... virus coding for interferon-β.
@en
type
label
Potent systemic therapy of mul ...... virus coding for interferon-β.
@ast
Potent systemic therapy of mul ...... virus coding for interferon-β.
@en
prefLabel
Potent systemic therapy of mul ...... virus coding for interferon-β.
@ast
Potent systemic therapy of mul ...... virus coding for interferon-β.
@en
P2093
P2860
P356
P1433
P1476
Potent systemic therapy of mul ...... virus coding for interferon-β.
@en
P2093
P2860
P2888
P304
P356
10.1038/CGT.2012.14
P577
2012-04-20T00:00:00Z